Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: CCK receptor and anxiety research
Also known as: GB115
GB-115 is a synthetic dipeptide (the amide of N-phenylhexanoyl-glycyl-L-tryptophan), designed as a retro-analog of cholecystokinin tetrapeptide (CCK-4). It acts as an antagonist at CCK-1 receptors, blocking cholecystokinin's anxiogenic signaling - a mechanism distinct from GABAergic sedatives such as benzodiazepines. Preclinical work in rhesus monkeys found subchronic GB-115 administration reduced emotional stress reactions and restored adaptive behavior under isolation conditions, comparable to the benzodiazepine phenazepam. A published human clinical study in patients with generalized anxiety disorder identified an effective dose of 6 mg/day, with a reportedly fast-onset anxiolytic effect, favorable effects on attention, reaction time, and sleep disturbances, and - unlike first-line SSRIs/SNRIs - no initial overactivation or anxiety worsening at treatment onset. GB-115 has reportedly completed Phase 3 trials for anxiety/adjustment disorders in Russia but is not approved outside Russia and is not FDA-approved.
Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.
Data source: Regional human clinical study and preclinical pharmacology
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Amounts and schedules are separated by administration route. Evidence badges distinguish labels, human studies, preclinical work, community reports, and evidence gaps.
2 mg three times daily
Context: clinical study PMID 31626171
Formulation: Oral-mucosal formulations are not dose-equivalent to injectable or topical formulations.
Route safety: Research-study protocol only; it is not an approved or individualized instruction and should not be extrapolated to another route.
Do not convert an amount between routes. Bioavailability, formulation, sterility, monitoring, and clinical context differ by route. Research-use context only; independently verify every cited source.
Reflects patterns reported in research/community literature only. Not a safety guarantee, medical advice, or interaction warning for human use.
The 6 mg/day regimen has a small regional clinical evidence base. Vendor capsule and liquid strengths are market context only.
Supplementary research context only. Not medical advice or a treatment recommendation.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.